Anusha Uttarilli, Sridhar Amalakanti, Phaneeswara-Rao Kommoju, Srihari Sharma, Pankaj Goyal, Gowrang Kasaba Manjunath, Vineet Upadhayay, Alisha Parveen, Ravi Tandon, Kumar Suranjit Prasad, Tikam Chand Dakal, Izhar Ben Shlomo, Malik Yousef, Muniasamy Neerathilingam, Abhishek Kumar
{"title":"Super-rapid race for saving lives by developing COVID-19 vaccines.","authors":"Anusha Uttarilli, Sridhar Amalakanti, Phaneeswara-Rao Kommoju, Srihari Sharma, Pankaj Goyal, Gowrang Kasaba Manjunath, Vineet Upadhayay, Alisha Parveen, Ravi Tandon, Kumar Suranjit Prasad, Tikam Chand Dakal, Izhar Ben Shlomo, Malik Yousef, Muniasamy Neerathilingam, Abhishek Kumar","doi":"10.1515/jib-2021-0002","DOIUrl":null,"url":null,"abstract":"<p><p>The pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people and claimed thousands of lives. Starting in China, it is arguably the most precipitous global health calamity of modern times. The entire world has rocked back to fight against the disease and the COVID-19 vaccine is the prime weapon. Even though the conventional vaccine development pipeline usually takes more than a decade, the escalating daily death rates due to COVID-19 infections have resulted in the development of fast-track strategies to bring in the vaccine under a year's time. Governments, companies, and universities have networked to pool resources and have come up with a number of vaccine candidates. Also, international consortia have emerged to address the distribution of successful candidates. Herein, we summarize these unprecedented developments in vaccine science and discuss the types of COVID-19 vaccines, their developmental strategies, and their roles as well as their limitations.</p>","PeriodicalId":53625,"journal":{"name":"Journal of Integrative Bioinformatics","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2021-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/jib-2021-0002","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Integrative Bioinformatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/jib-2021-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 13
Abstract
The pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people and claimed thousands of lives. Starting in China, it is arguably the most precipitous global health calamity of modern times. The entire world has rocked back to fight against the disease and the COVID-19 vaccine is the prime weapon. Even though the conventional vaccine development pipeline usually takes more than a decade, the escalating daily death rates due to COVID-19 infections have resulted in the development of fast-track strategies to bring in the vaccine under a year's time. Governments, companies, and universities have networked to pool resources and have come up with a number of vaccine candidates. Also, international consortia have emerged to address the distribution of successful candidates. Herein, we summarize these unprecedented developments in vaccine science and discuss the types of COVID-19 vaccines, their developmental strategies, and their roles as well as their limitations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
